Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA (COSIRA)
Primary Purpose
Refractory Angina
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Neovasc Reducer
Control
Sponsored by

About this trial
This is an interventional treatment trial for Refractory Angina
Eligibility Criteria
Inclusion Criteria:
- Patient is older than 18 years of age
- Symptomatic CAD with chronic refractory angina pectoris classified as Canadian Cardiovascular Society grade III or IV despite attempted optimal medical therapy for thirty days prior to screening
- Patient has limited treatment options for revascularization by coronary artery bypass grafting or by percutaneous coronary intervention
- Evidence of reversible ischemia that is attributable to the left coronary arterial system by Dobutamine Echo
- Left ventricular ejection fraction greater than 25%
- Male or non-pregnant female (NB: Females of child bearing potential must have a negative pregnancy test)
- Patient understands the nature of the procedure and provides written informed consent prior to enrollment
- Patient is willing to comply with specified follow-up evaluation and can be contacted by telephone
Exclusion Criteria:
- Recent (within three months) acute coronary syndrome
- Recent (within six months) successful PCI or CABG
- Unstable angina (recent onset angina, crescendo angina, or rest angina with ECG changes) during the thirty days prior to screening
- De-compensated congestive heart failure (CHF) or hospitalization due to CHF during the three months prior to screening
- Life threatening rhythm disorders or any rhythm disorders that would require placement of an internal defibrillator and or pacemaker
- Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second that is less than 55% of the predicted value
- Patient cannot undergo exercise tolerance test (bicycle) for reasons other than refractory angina
- Severe valvular heart disease
- Patient with pacemaker or defibrillator electrode in the right atrium, right ventricle, or coronary sinus
- Patient having undergone tricuspid valve replacement or repair
- Chronic renal failure (serum creatinine >2 mg/dL), including patients on chronic hemodialysis
- Moribund patients, or patients with comorbidities limiting life expectancy to less than one year
- Contraindication to required study medications that cannot be adequately controlled with pre-medication
- Known allergy to stainless steel or nickel
- Contraindication to having an MRI performed (NB: Cardiac MRI subset patients only)
- Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints
- Mean right atrial pressure higher than or equal to 15 mmHg
- Patient with anomalous or abnormal CS as demonstrated by angiogram. Abnormality defined as:
Abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left SVC) and/or; CS diameter at the site of planned reducer implantation less than 9.5 mm or greater than 13 mm
Sites / Locations
- ZNA Middelheim Hospital
- Ziekenhuis Oost-Limburg
- Ottawa Heart Institute
- Montreal Heart Institute
- Rigshospitalet
- UMC Utrecht
- Central Hospital Kristianstad
- Royal Infirmary of Bradford
- Royal Infirmary of Edinburgh
- King College Hospital
- Royal Brompton Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Reducer
Control
Arm Description
Implant Reducer
No treatment
Outcomes
Primary Outcome Measures
Canadian Cardiovascular Society Angina Score
A decrease of two or more Canadian Cardiovascular Society Angina Score grades from baseline to six-month post-procedural evaluation in Reducer and Control groups
Secondary Outcome Measures
Technical success
Successful delivery and deployment of the Reducer to the intended site as assessed by the investigator
Procedural success
Technical success and the absence of acute need for clinically-driven intervention to address an Adverse or Serious Adverse Device Effect prior to hospital discharge
Periprocedural Serious Adverse Event:
A composite of death, myocardial infarction, cardiac tamponade, clinically-driven re-dilation of a failed Reducer, life-threatening arrhythmia, and respiratory failure through 30 days post-procedure in the Reducer group.
Periprocedural Serious Adverse Event
A composite of death, myocardial infarction, cardiac tamponade, life-threatening arrhythmia, and respiratory failure through 30 days post-procedure in the control group.
Major Adverse Events
A composite of cardiac death, major stroke, and myocardial infarction in the Reducer and Control groups through hospital discharge, and at six-month post-procedural evaluations.
Canadian Cardiovascular Society Angina Score
A decrease one or more Canadian Cardiovascular Society Angina Score grades from baseline to six-month post-procedural evaluation in Reducer and Control groups
Dobutamine Echo Wall Motion Score Index
Wall motion score index in both the Reducer and control groups at baseline and six-month post-procedural evaluation
Seattle Angina Questionnaire Score
Seattle Angina Questionnaire in the Reducer and Control groups at baseline and six-month post-procedural evaluation
Exercise Tolerance Testing
Exercise Tolerance Testing in the Reducer and Control groups at baseline and six-month post-procedural evaluation
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01205893
Brief Title
Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA
Acronym
COSIRA
Official Title
Study to Confirm the Safety and Efficacy of the Reducer on Patients With Refractory Angina
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
November 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neovasc Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine if the Reducer is safe and effective in treating the symptoms of refractory angina in patients that suffer from refractory angina who demonstrate reversible ischemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractory Angina
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
104 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Reducer
Arm Type
Experimental
Arm Description
Implant Reducer
Arm Title
Control
Arm Type
Sham Comparator
Arm Description
No treatment
Intervention Type
Device
Intervention Name(s)
Neovasc Reducer
Intervention Description
Implantation of the Reducer
Intervention Type
Device
Intervention Name(s)
Control
Intervention Description
Control - No device implanted
Primary Outcome Measure Information:
Title
Canadian Cardiovascular Society Angina Score
Description
A decrease of two or more Canadian Cardiovascular Society Angina Score grades from baseline to six-month post-procedural evaluation in Reducer and Control groups
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Technical success
Description
Successful delivery and deployment of the Reducer to the intended site as assessed by the investigator
Time Frame
24 hours
Title
Procedural success
Description
Technical success and the absence of acute need for clinically-driven intervention to address an Adverse or Serious Adverse Device Effect prior to hospital discharge
Time Frame
24 hours
Title
Periprocedural Serious Adverse Event:
Description
A composite of death, myocardial infarction, cardiac tamponade, clinically-driven re-dilation of a failed Reducer, life-threatening arrhythmia, and respiratory failure through 30 days post-procedure in the Reducer group.
Time Frame
30 days
Title
Periprocedural Serious Adverse Event
Description
A composite of death, myocardial infarction, cardiac tamponade, life-threatening arrhythmia, and respiratory failure through 30 days post-procedure in the control group.
Time Frame
30 days
Title
Major Adverse Events
Description
A composite of cardiac death, major stroke, and myocardial infarction in the Reducer and Control groups through hospital discharge, and at six-month post-procedural evaluations.
Time Frame
6 months
Title
Canadian Cardiovascular Society Angina Score
Description
A decrease one or more Canadian Cardiovascular Society Angina Score grades from baseline to six-month post-procedural evaluation in Reducer and Control groups
Time Frame
6 months
Title
Dobutamine Echo Wall Motion Score Index
Description
Wall motion score index in both the Reducer and control groups at baseline and six-month post-procedural evaluation
Time Frame
6 months
Title
Seattle Angina Questionnaire Score
Description
Seattle Angina Questionnaire in the Reducer and Control groups at baseline and six-month post-procedural evaluation
Time Frame
6 months
Title
Exercise Tolerance Testing
Description
Exercise Tolerance Testing in the Reducer and Control groups at baseline and six-month post-procedural evaluation
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is older than 18 years of age
Symptomatic CAD with chronic refractory angina pectoris classified as Canadian Cardiovascular Society grade III or IV despite attempted optimal medical therapy for thirty days prior to screening
Patient has limited treatment options for revascularization by coronary artery bypass grafting or by percutaneous coronary intervention
Evidence of reversible ischemia that is attributable to the left coronary arterial system by Dobutamine Echo
Left ventricular ejection fraction greater than 25%
Male or non-pregnant female (NB: Females of child bearing potential must have a negative pregnancy test)
Patient understands the nature of the procedure and provides written informed consent prior to enrollment
Patient is willing to comply with specified follow-up evaluation and can be contacted by telephone
Exclusion Criteria:
Recent (within three months) acute coronary syndrome
Recent (within six months) successful PCI or CABG
Unstable angina (recent onset angina, crescendo angina, or rest angina with ECG changes) during the thirty days prior to screening
De-compensated congestive heart failure (CHF) or hospitalization due to CHF during the three months prior to screening
Life threatening rhythm disorders or any rhythm disorders that would require placement of an internal defibrillator and or pacemaker
Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second that is less than 55% of the predicted value
Patient cannot undergo exercise tolerance test (bicycle) for reasons other than refractory angina
Severe valvular heart disease
Patient with pacemaker or defibrillator electrode in the right atrium, right ventricle, or coronary sinus
Patient having undergone tricuspid valve replacement or repair
Chronic renal failure (serum creatinine >2 mg/dL), including patients on chronic hemodialysis
Moribund patients, or patients with comorbidities limiting life expectancy to less than one year
Contraindication to required study medications that cannot be adequately controlled with pre-medication
Known allergy to stainless steel or nickel
Contraindication to having an MRI performed (NB: Cardiac MRI subset patients only)
Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints
Mean right atrial pressure higher than or equal to 15 mmHg
Patient with anomalous or abnormal CS as demonstrated by angiogram. Abnormality defined as:
Abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left SVC) and/or; CS diameter at the site of planned reducer implantation less than 9.5 mm or greater than 13 mm
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Verheye, MD
Organizational Affiliation
ZNA Middelheim Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
ZNA Middelheim Hospital
City
Antwerpen
ZIP/Postal Code
2020
Country
Belgium
Facility Name
Ziekenhuis Oost-Limburg
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Facility Name
Ottawa Heart Institute
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4W7
Country
Canada
Facility Name
Montreal Heart Institute
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 1C8
Country
Canada
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
DK-2100
Country
Denmark
Facility Name
UMC Utrecht
City
Utrecht
ZIP/Postal Code
3584
Country
Netherlands
Facility Name
Central Hospital Kristianstad
City
Kristianstad
ZIP/Postal Code
85
Country
Sweden
Facility Name
Royal Infirmary of Bradford
City
Bradford
Country
United Kingdom
Facility Name
Royal Infirmary of Edinburgh
City
Edinburgh
ZIP/Postal Code
EH16 4SA
Country
United Kingdom
Facility Name
King College Hospital
City
London
ZIP/Postal Code
SE5 9RS
Country
United Kingdom
Facility Name
Royal Brompton Hospital
City
London
ZIP/Postal Code
SW3 6NP
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
32719097
Citation
Jolicoeur EM, Verheye S, Henry TD, Joseph L, Doucet S, White CJ, Edelman E, Banai S. A novel method to interpret early phase trials shows how the narrowing of the coronary sinus concordantly improves symptoms, functional status and quality of life in refractory angina. Heart. 2021 Jan;107(1):41-46. doi: 10.1136/heartjnl-2020-316644. Epub 2020 Jul 21.
Results Reference
derived
PubMed Identifier
25651246
Citation
Verheye S, Jolicoeur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, Vrolix M, Agostoni P, Engstrom T, Labinaz M, de Silva R, Schwartz M, Meyten N, Uren NG, Doucet S, Tanguay JF, Lindsay S, Henry TD, White CJ, Edelman ER, Banai S. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015 Feb 5;372(6):519-27. doi: 10.1056/NEJMoa1402556.
Results Reference
derived
PubMed Identifier
23413981
Citation
Jolicoeur EM, Banai S, Henry TD, Schwartz M, Doucet S, White CJ, Edelman E, Verheye S. A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial. Trials. 2013 Feb 15;14:46. doi: 10.1186/1745-6215-14-46.
Results Reference
derived
Learn more about this trial
Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA
We'll reach out to this number within 24 hrs